Cargando…
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
INTRODUCTION: Levodopa/carbidopa intestinal gel (LCIG; carbidopa/levodopa enteral suspension) has been widely used and studied for the treatment of motor fluctuations in levodopa-responsive patients with advanced Parkinson’s disease (PD) when other treatments have not given satisfactory results. Red...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189983/ https://www.ncbi.nlm.nih.gov/pubmed/34018146 http://dx.doi.org/10.1007/s12325-021-01747-1 |
_version_ | 1783705597430988800 |
---|---|
author | Antonini, Angelo Odin, Per Pahwa, Rajesh Aldred, Jason Alobaidi, Ali Jalundhwala, Yash J. Kukreja, Pavnit Bergmann, Lars Inguva, Sushmitha Bao, Yanjun Chaudhuri, K. Ray |
author_facet | Antonini, Angelo Odin, Per Pahwa, Rajesh Aldred, Jason Alobaidi, Ali Jalundhwala, Yash J. Kukreja, Pavnit Bergmann, Lars Inguva, Sushmitha Bao, Yanjun Chaudhuri, K. Ray |
author_sort | Antonini, Angelo |
collection | PubMed |
description | INTRODUCTION: Levodopa/carbidopa intestinal gel (LCIG; carbidopa/levodopa enteral suspension) has been widely used and studied for the treatment of motor fluctuations in levodopa-responsive patients with advanced Parkinson’s disease (PD) when other treatments have not given satisfactory results. Reduction in ‘off’-time is a common primary endpoint in studies of LCIG, and it is important to assess the durability of this response. This systematic literature review was conducted to qualitatively summarise the data on the long-term effects of LCIG therapy on ‘off’-time. METHODS: Studies were identified by searching PubMed, EMBASE and Ovid on 30 September 2019. Studies were included if they reported on patients with PD, had a sample size of ≥ 10, LCIG was an active intervention and ‘off’-time was reported for ≥ 12 months after initiation of LCIG treatment. Randomised clinical trials, retrospective and prospective observational studies, and other interventional studies were included for selection. Data were collected on: ‘off’-time (at pre-specified time periods and the end of follow-up), study characteristics, Unified Parkinson’s Disease Rating Scale (UPDRS) II, III and IV total scores, dyskinesia duration, quality of life scores, non-motor symptoms and safety outcomes. RESULTS: Twenty-seven studies were included in this review. The improvement in ‘off’-time observed shortly after initiating LCIG was maintained and was statistically significant at the end of follow-up in 24 of 27 studies. ‘Off’-time was reduced from baseline to end of follow-up by 38–84% and was accompanied by a clinically meaningful improvement in quality of life. Stratified analysis of ‘off’-time demonstrated mean relative reductions of 47–82% at 3–6 months and up to 83% reduction at 3–5 years of follow-up. Most studies reported significant improvements in activities of daily living and motor complications. Most frequent adverse events were related to the procedure or the device. CONCLUSION: In one of the largest qualitative syntheses of published LCIG studies, LCIG treatment was observed to provide a durable effect in reducing ‘off’-time. INFOGRAPHIC: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01747-1. |
format | Online Article Text |
id | pubmed-8189983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-81899832021-06-28 The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review Antonini, Angelo Odin, Per Pahwa, Rajesh Aldred, Jason Alobaidi, Ali Jalundhwala, Yash J. Kukreja, Pavnit Bergmann, Lars Inguva, Sushmitha Bao, Yanjun Chaudhuri, K. Ray Adv Ther Review INTRODUCTION: Levodopa/carbidopa intestinal gel (LCIG; carbidopa/levodopa enteral suspension) has been widely used and studied for the treatment of motor fluctuations in levodopa-responsive patients with advanced Parkinson’s disease (PD) when other treatments have not given satisfactory results. Reduction in ‘off’-time is a common primary endpoint in studies of LCIG, and it is important to assess the durability of this response. This systematic literature review was conducted to qualitatively summarise the data on the long-term effects of LCIG therapy on ‘off’-time. METHODS: Studies were identified by searching PubMed, EMBASE and Ovid on 30 September 2019. Studies were included if they reported on patients with PD, had a sample size of ≥ 10, LCIG was an active intervention and ‘off’-time was reported for ≥ 12 months after initiation of LCIG treatment. Randomised clinical trials, retrospective and prospective observational studies, and other interventional studies were included for selection. Data were collected on: ‘off’-time (at pre-specified time periods and the end of follow-up), study characteristics, Unified Parkinson’s Disease Rating Scale (UPDRS) II, III and IV total scores, dyskinesia duration, quality of life scores, non-motor symptoms and safety outcomes. RESULTS: Twenty-seven studies were included in this review. The improvement in ‘off’-time observed shortly after initiating LCIG was maintained and was statistically significant at the end of follow-up in 24 of 27 studies. ‘Off’-time was reduced from baseline to end of follow-up by 38–84% and was accompanied by a clinically meaningful improvement in quality of life. Stratified analysis of ‘off’-time demonstrated mean relative reductions of 47–82% at 3–6 months and up to 83% reduction at 3–5 years of follow-up. Most studies reported significant improvements in activities of daily living and motor complications. Most frequent adverse events were related to the procedure or the device. CONCLUSION: In one of the largest qualitative syntheses of published LCIG studies, LCIG treatment was observed to provide a durable effect in reducing ‘off’-time. INFOGRAPHIC: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01747-1. Springer Healthcare 2021-05-20 2021 /pmc/articles/PMC8189983/ /pubmed/34018146 http://dx.doi.org/10.1007/s12325-021-01747-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Antonini, Angelo Odin, Per Pahwa, Rajesh Aldred, Jason Alobaidi, Ali Jalundhwala, Yash J. Kukreja, Pavnit Bergmann, Lars Inguva, Sushmitha Bao, Yanjun Chaudhuri, K. Ray The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review |
title | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review |
title_full | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review |
title_fullStr | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review |
title_full_unstemmed | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review |
title_short | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review |
title_sort | long-term impact of levodopa/carbidopa intestinal gel on ‘off’-time in patients with advanced parkinson’s disease: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189983/ https://www.ncbi.nlm.nih.gov/pubmed/34018146 http://dx.doi.org/10.1007/s12325-021-01747-1 |
work_keys_str_mv | AT antoniniangelo thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT odinper thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT pahwarajesh thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT aldredjason thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT alobaidiali thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT jalundhwalayashj thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT kukrejapavnit thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT bergmannlars thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT inguvasushmitha thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT baoyanjun thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT chaudhurikray thelongtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT antoniniangelo longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT odinper longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT pahwarajesh longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT aldredjason longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT alobaidiali longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT jalundhwalayashj longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT kukrejapavnit longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT bergmannlars longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT inguvasushmitha longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT baoyanjun longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview AT chaudhurikray longtermimpactoflevodopacarbidopaintestinalgelonofftimeinpatientswithadvancedparkinsonsdiseaseasystematicreview |